Every constituent, scored 0–10 on Downside Risk (lower = safer), Growth Quality, and Exponential Potential, with price, YTD, a base-case fair value (and its bear–bull range), and a one-line take. Click a ticker for the full interactive report. ← research hub
◆ Accumulation band for XLV itself: roughly $150–$164 — the index is richly priced, so dollar-cost-averaging on dips toward the 50/200-day average (near $150) beats chasing new highs.
XLV (market-cap-weighted) vs RSPH (equal-weight), both rebased to 100 a year ago. When the cap-weighted line pulls ahead, the biggest names are carrying the index. Past year: XLV +21% vs RSPH +18% — a +3 pt spread, so a few mega-caps are carrying the index — concentration is ELEVATED.
How many of the 8 names are actually participating — a check on whether the index is broad-based or driven by a handful of mega-caps. Right now breadth looks mixed.
| Name | Verdict | Risk | Growth | Exp | Price | YTD | Fair value (range) | Entry zone | One-line take |
|---|---|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems Inc. | Buy — Core | 4 | 8 | 4 | — | -13.7% | $235 ($150–$300) | — | Veeva is the near-monopoly cloud platform for the life-sciences industry — 75% gross margin, net-cash balance sheet, ~$3.2B revenue growing 16% — that the market has taken from a ~$310 peak down to $193 (a −43% drawdown) as growth cooled from hypergrowth to the mid-teens; at ~21× forward non-GAAP… |
| LLY Eli Lilly and Company | Buy — Tactical | 5 | 9 | 5 | — | +12.6% | $1430 ($800–$1880) | — | The rare megacap where the fundamentals (FY25 revenue +45% to $65B, 84% gross margin, net income $20.6B) and an unusually broad, high-quality expert panel point the same way — owned as a core compounder, not a bargain, with the whole call resting on the next-gen pipeline replacing tirzepatide… |
| VRTX Vertex Pharmaceuticals Incorpora | Buy — Tactical | 4 | 7 | 5 | $528 | +16.5% | $585 ($395–$725) | $447–$528 | Vertex is the most profitable pure biotech at scale — an 86%-gross-margin, net-cash monopoly in cystic fibrosis throwing off ~$3.2B of free cash flow — now trying to prove it can diversify beyond CF (Journavx non-opioid pain, Casgevy gene therapy, kidney and type-1-diabetes programs). It is a… |
| A Agilent Technologies, Inc. | Buy — Tactical | 4 | 6 | 3 | — | -4.0% | $145 ($112–$172) | — | Agilent is a genuinely high-quality, recurring-revenue lab-instruments compounder — 53% gross margin, 21% ROE, strong free cash flow, low leverage — but it is growing revenue only mid-single-digits, the multiple already reflects the quality, and there is no expert conviction behind it, so it… |
| GILD Gilead Sciences, Inc. | Buy — Tactical | 3 | 5 | 3 | $131 | +6.9% | $146 ($102–$179) | $130–$131 | Gilead is a cheap, cash-gushing HIV franchise (79% gross margin, 6.3% FCF yield, 2.45% dividend, 1.0× net-debt/EBITDA) trading at ~18× earnings — a defensive income-and-value holding whose entire re-rating case rests on lenacapavir/Yeztugo extending the HIV moat past the Biktarvy cliff, with no… |
| CI The Cigna Group | Buy — Tactical | 4 | 5 | 2 | — | +4.6% | $330 ($235–$400) | — | Cigna is a $275B-revenue health-services giant trading at a *single-digit* forward earnings multiple with a 0.30 beta and ~$8B of annual free cash flow — genuinely cheap and defensive — but the cheapness is the whole point: it is a low-margin, slow-growth, buyback-driven PBM/insurer facing real… |
| ALGN Align Technology, Inc. | Buy — Tactical | 5 | 5 | 3 | — | +18.2% | $210 ($155–$252) | — | Align is the category-defining clear-aligner and iTero-scanner franchise (68% gross margin, net-cash balance sheet, ~$490M FCF), but revenue has essentially stopped growing (FY25 +0.9%), the stock has lagged the market for a year, and at ~16× forward non-GAAP earnings it is *fairly* — not cheaply… |
| COO The Cooper Companies, Inc. | Buy — Tactical | 5 | 5 | 3 | — | -9.5% | $95 ($70–$118) | — | Cooper is a defensive, low-beta medical-device duopolist (contact lenses + women's health) trading at a reasonable ~15–16× forward non-GAAP earnings after a rough year, but the top line only grows mid-single-digits, returns on capital are mediocre, a fresh $272M litigation charge just landed, and… |
| ELV Elevance Health Inc. | Buy — Tactical | 5 | 5 | 3 | — | +19.2% | $465 ($300–$590) | — | ELV is a cheap, low-beta health-benefits giant (~118M members, ~$199B revenue) trading at ~14× forward *adjusted* EPS because the market is (correctly) worried about a Medicaid medical-cost cycle and a live CMS billing matter — a Buy — Tactical for value/mean-reversion investors who can stomach a… |
| UNH UnitedHealth Group Incorporated | Buy — Tactical | 5 | 5 | 3 | — | +28.9% | $470 ($300–$610) | — | UNH is the largest US health insurer whose earnings *cratered* in 2025 (EPS $24 → $13) on runaway senior medical costs and a Medicare Advantage reset; the stock fell to $234, and the entire bull case is that management's repricing and cost actions restore earnings power — trading at ~23× a… |
| PODD Insulet Corporation | Watch | 5 | 8 | 6 | — | -42.1% | $195 ($112–$252) | — | Insulet is the tubeless-insulin-pump leader still compounding revenue ~30%+ (FY25 $2.71B, +30.7%) with expanding margins and modest leverage, yet the stock has been cut in half from its 2025 peak — a rare case where a genuine ~20% grower now trades at ~20× next-year earnings; the catch is that… |
| BSX Boston Scientific Corporation | Watch | 5 | 7 | 4 | — | -52.7% | $67 ($40–$87) | — | Boston Scientific is a genuinely good medical-device business — FY25 revenue +20% to $20.1B, 70% gross margin, adjusted EPS guided to $3.34–$3.41 for FY26 — that has been cut roughly in half over twelve months; if the fundamentals hold (Q1'26 beat and management *raised* the full-year outlook), 13×… |
| SYK Stryker Corporation | Watch | 5 | 7 | 3 | — | -7.1% | $385 ($295–$455) | — | Stryker is a genuinely elite medical-device compounder — two decades of double-digit growth, a widening Mako robotics moat, 64% gross margins — but after a cyber incident dented Q1'26 (adjusted EPS −8.5%, adjusted operating margin −180bp), the stock trades at ~22× forward adjusted earnings on… |
| ABT Abbott Laboratories | Watch | 3 | 6 | 3 | — | -23.9% | $112 ($77–$140) | — | Abbott is a defensive, diversified medtech compounder whose stock has fallen ~30% in a year to ~17× forward EPS — cheap for a business with a genuinely great growth engine (FreeStyle Libre CGM, structural heart) — but the growth is modest (~9% top line) and decelerating, and the Synthos expert… |
| MCK McKesson Corporation | Watch | 3 | 6 | 3 | — | -4.1% | $880 ($620–$1050) | — | McKesson is a boring, cash-generative pharmaceutical-distribution utility trading at ~18× forward guidance with a fortress-cheap balance sheet (0.66× net-debt/EBITDA, beta 0.32) and management guiding 13–16% long-term adjusted-EPS growth funded by scale, oncology/biopharma mix-shift and relentless… |
| REGN Regeneron Pharmaceuticals, Inc. | Watch | 4 | 6 | 4 | $654 | -15.2% | $785 ($490–$1010) | — | Regeneron is a rare cheap large-cap biotech — 15× trailing earnings, net cash, 84% gross margin — where the market has repriced the stock for a shrinking Eylea franchise (−46% peak-to-trough), while Dupixent (a Sanofi-shared blockbuster still growing double digits) and a broad late-stage pipeline… |
| RMD ResMed Inc. | Watch | 4 | 6 | 3 | — | -13.0% | $255 ($190–$338) | — | ResMed is a dominant, cash-generative, net-cash medical-device franchise (FY25 revenue $5.15B, 24% ROE, ~$1.66B FCF) that has been sold down ~29% from its high on fears that GLP-1 weight-loss drugs will erode its sleep-apnea market — yet it keeps posting ~10–11% revenue growth and margin expansion… |
| STE STERIS plc | Watch | 4 | 6 | 3 | — | -13.9% | $235 ($175–$285) | — | STERIS is a boring-in-a-good-way infection-prevention near-monopoly — FY26 revenue $5.94B (+9% reported / +7% organic), record adjusted EPS $10.17, FCF $983M, net-debt/EBITDA under 1× — but the stock is down ~10% over the past year and still trades at a full ~27× trailing GAAP earnings for only… |
| UHS Universal Health Services, Inc. | Watch | 4 | 6 | 3 | — | -27.4% | $245 ($150–$330) | — | UHS is a well-run, US-focused hospital and behavioral-health operator trading at ~6.7× earnings and 5.3× EV/EBITDA — a genuine value setup where a big price drop (−35% from the high) has collided with rising earnings ($23.10 EPS in FY25, +37% YoY) and heavy buybacks; the whole call is a re-rating +… |
| DHR Danaher Corporation | Watch | 5 | 6 | 3 | — | -13.5% | $219 ($160–$260) | — | Danaher is a genuinely elite operator (60%+ gross margin, ~75% recurring revenue, strong free cash flow) that has become a *slow* compounder after its post-COVID bioprocessing hangover — sales grew just +2.9% in FY25 and are modeled at only ~5% forward, so at 23× forward adjusted earnings there is… |
| TMO Thermo Fisher Scientific Inc. | Watch | 5 | 6 | 3 | — | -9.7% | $560 ($420–$700) | — | Thermo Fisher is the "picks-and-shovels" leader of the life-sciences economy — a wide-moat, cash-generative compounder — but it is currently a ~6% revenue grower trading at ~21× forward earnings, with organic growth stalled near 1% and the stock near a full multiple, so the honest verdict is Watch… |
| IDXX IDEXX Laboratories, Inc. | Hold | 5 | 8 | 3 | $558 | -17.5% | $565 ($390–$720) | — | IDEXX is a genuinely elite, wide-moat razor-and-blade franchise (62% gross margin, 40% ROIC, 71% ROE, recurring consumable revenue) — but after a −27% drawdown it *still* trades at 41× trailing earnings while growth has settled into the ~10% range, so the quality is real and the price is the… |
| ISRG Intuitive Surgical, Inc. | Hold | 6 | 8 | 5 | $426 | -24.8% | $430 ($300–$640) | — | Intuitive is one of the highest-quality medical-device franchises on the market — a razor-and-blade robotic-surgery near-monopoly with a fortress net-cash balance sheet and ~13.5–15.5% guided procedure growth — but the stock has already fallen ~30% from its high while still trading at 51× earnings… |
| DXCM DexCom, Inc. | Hold | 6 | 7 | 4 | $71 | +7.4% | $72 ($48–$100) | — | DexCom is the most accurate continuous glucose monitor and owns the insulin-intensive diabetes segment with a long penetration runway — but growth has decelerated from ~25%+ to management's own ~11–13% FY26 guide, the stock still trades at ~30× earnings after a −56% peak-to-trough drawdown, and the… |
| WST West Pharmaceutical Services, In | Hold | 6 | 7 | 4 | — | +32.9% | $316 ($225–$395) | — | West is a genuinely elite "picks-and-shovels" franchise — the dominant maker of the rubber stoppers, seals and delivery components that go into virtually every injectable drug, with a fortress net-cash balance sheet and best-in-class returns on capital — but after a +64% twelve-month rally to a… |
| ABBV AbbVie Inc. | Hold | 6 | 6 | 3 | — | +14.3% | $275 ($205–$330) | — | AbbVie has done the hard thing — replaced its $21B Humira monopoly with Skyrizi + Rinvoq ($25.9B combined in FY25 and still growing 20–30%) — so the growth cliff everyone feared is now behind it; but the stock sits at an all-time high on ~18× forward adjusted earnings with 3.8× net leverage and… |
| EW Edwards Lifesciences Corporation | Hold | 6 | 6 | 4 | — | +10.7% | $90 ($66–$116) | — | Edwards is a genuinely excellent, focused structural-heart franchise — 78% gross margin, net-cash balance sheet, category leadership in transcatheter aortic valves (TAVR) — but at ~50× trailing / 31× forward EPS on a business the Street models growing revenue ~10% a year, the price already reflects… |
| HCA HCA Healthcare, Inc. | Hold | 6 | 6 | 3 | — | -12.1% | $500 ($360–$578) | — | HCA is the largest for-profit hospital operator in the US — a genuinely cheap (13.6× FY26E), high-return (~19% ROIC), prodigious cash generator that shrinks its share count aggressively — but it carries heavy leverage (3.1× net-debt/EBITDA, negative book equity) and sits directly in the path of two… |
| IQV IQVIA Holdings Inc. | Hold | 6 | 6 | 3 | — | -8.1% | $227 ($156–$270) | — | IQVIA is the dominant global data-and-clinical-research franchise (FY25 revenue $16.3B, +5.9%; adjusted EPS re-accelerating; FCF ~100% of adjusted net income) trading at a reasonable ~16× forward adjusted earnings — the catch is 4× net leverage, a 1.2 beta, and an order book that lives and dies on… |
| MTD Mettler-Toledo International Inc | Hold | 6 | 6 | 3 | — | -6.2% | $1290 ($980–$1620) | — | Mettler-Toledo is one of the highest-quality industrial-instruments businesses on the market — 58% gross margins, ~36% ROIC, relentless buybacks — but it grows revenue only mid-single-digits, the multiple already embeds that quality, and the stock is technically stretched (RSI 82) below its… |
| WAT Waters Corporation | Hold | 6 | 6 | 4 | — | -0.1% | $400 ($300–$500) | — | Waters is a best-in-class "razor-and-blades" analytical-instruments franchise — sticky consumables and service on top of high-end liquid-chromatography and mass-spec hardware — that just doubled its revenue base by acquiring BD's Biosciences and Diagnostic Solutions units (closed Feb 9, 2026); the… |
| CAH Cardinal Health, Inc. | Hold | 4 | 5 | 2 | — | +16.3% | $256 ($165–$330) | — | Cardinal Health is a boring, essential, low-margin drug-distribution oligopolist that has quietly executed a genuine turnaround (non-GAAP EPS guided +30% to ~$10.75 in FY26, leverage cut to 3.0×, $1B bought back) — but the market has *already* rewarded it, running the stock to a fresh 52-week high… |
| COR Cencora, Inc. | Hold | 4 | 5 | 3 | — | -12.2% | $340 ($255–$400) | — | Cencora is a defensive, low-beta pharmaceutical-distribution utility moving $321B of drugs a year at a ~3.5% gross margin and <1% net margin; the stock has de-rated ~21% off its high and trades at ~16.7× forward adjusted EPS with a mid-teens adjusted-EPS growth path driven by buybacks, mix… |
| DGX Quest Diagnostics Incorporated | Hold | 4 | 5 | 2 | — | +24.3% | $220 ($165–$265) | — | Quest is a well-run, defensive US clinical-lab duopolist growing high-single-digit revenue (FY25 +11.8% to $11.0B, mostly M&A-assisted) with reliable cash flow and a 1.5% dividend — but at 24× trailing earnings and 3.1× net-debt/EBITDA on ~11% EPS growth, the stock already reflects the good news… |
| JNJ Johnson & Johnson | Hold | 4 | 5 | 2 | — | +27.1% | $258 ($205–$300) | — | Johnson & Johnson is a fortress: AAA-caliber balance sheet, 0.26 beta, 69% gross margin, two diversified franchises (Innovative Medicine + MedTech), and a raised FY26 outlook — but after a +69% twelve-month run it trades at 30× trailing / 22.7× forward for only mid-single-digit revenue growth, so… |
| GEHC GE HealthCare Technologies Inc. | Hold | 5 | 5 | 3 | $66 | -20.1% | $75 ($52–$95) | — | GE HealthCare is a global imaging and diagnostics leader trading at a genuinely undemanding valuation (13× forward earnings, 1.9× sales), backed by a rock-solid installed base and a helpful cluster of insider buying — but it grows revenue at only mid-single-digits, carries moderate leverage, and… |
| ZTS Zoetis Inc. | Hold | 5 | 5 | 3 | — | -40.5% | $84 ($58–$112) | — | Zoetis is the world's #1 animal-health company — 71% gross margins, 62% ROE, a genuine moat — now trading at a 5-year-low 12× earnings after a brutal −53% drawdown; but the crash reflects a *real* stall (US companion-animal demand softening, generics on Convenia/Cerenia, dermatology competition)… |
| AMGN Amgen Inc. | Hold | 6 | 5 | 3 | $374 | +14.3% | $380 ($270–$470) | — | Amgen is a high-margin, cash-generative big-pharma cash-cow (FY25 revenue $36.7B +9.9%, 71% gross margin, $8.1B FCF, 2.6% dividend) trading at a reasonable ~16–17× forward adjusted earnings — but it grows revenue at only ~3% a year, carries $45B of net debt against a buyback-hollowed balance sheet… |
| HUM Humana Inc. | Hold | 6 | 5 | 4 | — | +54.9% | $360 ($230–$500) | — | Humana is a #2 Medicare Advantage insurer whose GAAP earnings collapsed (FY25 adjusted EPS $17.14 → FY26 guided "at least $9.00") on a Bonus-Year-2026 Star Ratings funding headwind; the stock has already tripled off its 2025 lows (+124% in three months) on the bet that Stars and margins normalize… |
| INCY Incyte Corporation | Hold | 6 | 5 | 3 | — | +18.3% | $105 ($72–$135) | — | Incyte looks statistically cheap — 16× earnings, net cash, 92% gross margin, a 21% top-line year — but that low multiple is the market correctly pricing a concentration problem: Jakafi is ~69% of revenue and its exclusivity cliff is already visible in consensus (EPS peaks near $9.47 in FY28E then… |
| RVTY Revvity, Inc. | Hold | 6 | 5 | 3 | — | +17.6% | $116 ($82–$150) | — | Revvity is a high-quality, recurring-revenue diagnostics and life-sciences-tools franchise that is executing fine operationally — beating its own quarterly numbers — but is growing only 3–4% organically, carries 3.2× net-debt/EBITDA, and already trades roughly in line with a fair value, so there is… |
| TECH Bio-Techne Corporation | Hold | 6 | 5 | 3 | — | +20.4% | $63 ($46–$82) | — | Bio-Techne is a genuinely high-quality life-science-tools franchise — 65% gross margins, sticky consumables, a fortress balance sheet — but after a −2% revenue quarter and a re-based ~5% forward growth rate, the stock has run to ~35× forward earnings and an RSI of 84 near its 52-week high, *above*… |
| MDT Medtronic plc | Hold | 4 | 4 | 2 | — | -13.4% | $88 ($66–$108) | — | Medtronic is a cheap, ultra-diversified med-device blue-chip throwing off a 3.4% dividend it has raised for 49 straight years — FY26 delivered its best organic growth in a decade (+5.8%) — but ~6% organic top-line, flat margins, ~6% ROIC and a stock 21% below its high and trailing the market by ~27… |
| SOLV Solventum Corporation | Hold | 4 | 4 | 2 | — | -1.2% | $88 ($58–$102) | — | Solventum is 3M's former healthcare arm, spun out in 2024, trading at a genuine discount (9.5× earnings, 6.6× EV/EBITDA) because the market prices it as a low-growth, over-levered carve-out — the whole bull case is that management deleverages (net debt already cut from $8.1B to $4.2B), stabilizes… |
| BDX Becton, Dickinson and Company | Hold | 5 | 4 | 2 | — | +3.6% | $181 ($126–$232) | — | BD is a boring, cash-generative medical-technology "razor-and-blades" business — syringes, catheters, infusion pumps, pre-fillable drug-delivery systems — that the market has left for dead at ~12.5× forward adjusted earnings after years of tepid growth and a just-completed spin of its Life Sciences… |
| BIIB Biogen Inc. | Hold | 5 | 4 | 3 | — | +22.8% | $220 ($150–$300) | — | Biogen is a cheap (~15× forward), fortress-balance-sheet, ultra-low-beta pharma whose legacy neurology franchise is in structural decline — the entire investment case is whether Leqembi (Alzheimer's, with Eisai) plus a re-tooled pipeline can *stabilize* revenue around ~$10B and let cost discipline… |
| HSIC Henry Schein, Inc. | Hold | 5 | 4 | 3 | — | +14.4% | $88 ($62–$108) | — | Henry Schein is the world's largest dental/medical distributor — a genuinely defensive, sticky, low-beta business — but it is a low-growth, thin-margin, moderately levered compounder whose ~+2% upside to fair value offers no real margin of safety; there is no expert conviction behind it, so it… |
| LH Labcorp Holdings Inc. | Hold | 5 | 4 | 2 | — | +14.4% | $300 ($225–$360) | — | Labcorp is a well-run, defensive diagnostics-and-CRO duopolist throwing off ~$1.2B of free cash flow, but it grows revenue only in the low-single-digits and trades roughly in line with fair value — a fine business at a fair price, which is a Watch, not a buy: you are paid to wait, not to win. |
| MRK Merck & Co., Inc. | Hold | 5 | 4 | 3 | — | +23.0% | $130 ($95–$165) | — | Merck is a cheap, cash-generative, low-beta mega-cap trading at ~13.5× FY27E earnings — but the discount is *earned*: its one megablockbuster, Keytruda, is roughly $30B of the ~$58B pharma business and faces a 2028 US patent cliff, so the top line is stalling (FY25 revenue +1.2%) right as the… |
| ZBH Zimmer Biomet Holdings, Inc. | Hold | 5 | 4 | 2 | — | -2.7% | $108 ($76–$133) | — | Zimmer Biomet is a cheap, cash-generative, low-beta orthopedic-implant leader (FY25 revenue $8.23B, ~10× forward adjusted earnings, ~8.7% FCF yield) whose stock has de-rated on years of low-single-digit organic growth and rising leverage — a tactical value buy where the payoff is multiple re-rating… |
| CNC Centene Corp. | Hold | 6 | 4 | 3 | — | +64.9% | $68 ($40–$80) | — | Centene is a ~$195B-revenue Medicaid/government managed-care giant priced for distress (13% free-cash-flow yield, 0.14× EV/sales) that is visibly recovering — Q1'26 adjusted EPS of $3.37 beat by ~$0.50 and management *raised* FY26 adjusted-EPS guidance to ">$3.40" — but the earnings are… |
| CVS CVS Health Corporation | Hold | 6 | 4 | 3 | — | +32.0% | $118 ($72–$150) | — | CVS is a $402B-revenue integrated health giant coming off a brutal 2025 (a Q3 loss dragged full-year GAAP EPS to $1.39) that is now visibly recovering — Q1'26 adjusted EPS $2.57 beat and management *raised* full-year 2026 guidance — and the stock, up 50% in a year, trades at ~14× current-year… |
| DVA DaVita Inc. | Hold | 7 | 4 | 2 | — | +106.8% | $205 ($150–$265) | — | DaVita is a genuinely dominant, cash-generative dialysis duopolist whose *earnings* keep rising — but almost entirely through a shrinking share count (buybacks), not organic growth; with the stock up 60% in a year to a fresh high, an RSI of 91, and a price now above every analyst target, the… |
| BMY Bristol-Myers Squibb Company | Hold | 5 | 3 | 2 | — | +7.8% | $60 ($42–$78) | — | BMY is a cheap, high-yield, cash-generative pharma trading at 16× trailing / ~9× forward earnings and a ~10% free-cash-flow yield — but the low multiple is the market correctly pricing a shrinking revenue base: consensus has sales falling from ~$48B (2025) toward ~$37B (2030) as Eliquis (2028 US… |
| PFE Pfizer Inc. | Hold | 5 | 3 | 2 | — | -2.3% | $26 ($18–$31) | — | Pfizer is a cheap, 7%-yielding mega-pharma that has fully round-tripped its COVID windfall (revenue $100B in 2022 → $62.6B in 2025) and now faces a wall of patent expirations that consensus expects to *shrink* revenue toward ~$53B by 2030 — the entire bull case is whether obesity, oncology… |
| BAX Baxter International Inc. | Hold | 6 | 3 | 2 | — | +18.5% | $25 ($18–$33) | — | Post-Kidney-Care spin, Baxter is a slimmed-down, essential-hospital-products medtech trading at a genuinely cheap ~12× forward adjusted EPS with a low 0.61 beta — but it is a mid-turnaround, not a compounder: revenue is flat-to-down organically, GAAP earnings are still negative, and ~$8B of net… |
| CRL Charles River Laboratories Inter | Hold | 6 | 3 | 2 | — | +15.6% | $220 ($165–$300) | — | Charles River is a genuinely high-quality, wide-moat contract research organization (the dominant supplier of research models and preclinical safety testing) caught in a cyclical demand trough — revenue is flat-to-declining, management itself guides 2026 organic revenue *down*, and after a sharp… |
| MRNA Moderna, Inc. | Avoid | 8 | 3 | 5 | — | +170.5% | $42 ($18–$85) | — | Moderna is a cash-rich but deeply loss-making mRNA platform whose COVID franchise has collapsed (FY25 revenue $1.94B, −39% YoY; net loss −$2.8B), and the stock has tripled in a year on pipeline hope into a 52-week high with an RSI of 86 — yet the Street's own price target is ~44% below spot. The… |
| VTRS Viatris Inc. | Avoid | 6 | 2 | 1 | — | +34.1% | $19 ($13–$26) | — | Viatris is a cheap, cash-generative, dividend-paying generics-and-brands business trading at ~7× forward *adjusted* earnings with a ~10% free-cash-flow yield — the value is real, but so is the ~$13.4B net debt and a top line that management itself guides to be roughly *flat*; you are paid to wait… |